<DOC>
	<DOCNO>NCT02974010</DOCNO>
	<brief_summary>NeuroRx develop NRX-101 , fixed-dose combination oral capsule compose d-cycloserine ( DCS ) lurasidone maintenance remission Acute Suicidal Ideation ( C-SSRS level 4 5 ) Behavior ( ASIB ) adult Bipolar Depression follow initial stabilization . Patients Bipolar Depression ASIB recruit inpatient outpatient setting , follow informed consent , give intravenous infusion ketamine 0.5mg/kg 40 minute . Those exhibit satisfactory clinical response ketamine randomly allocate NRX-101 comparator group . The primary outcome variable time relapse define return baseline either depression suicidality determine treat physician need institute new treatment plan .</brief_summary>
	<brief_title>STABIL-B Trial NRX-101 Acute Suicidal Ideation Behavior</brief_title>
	<detailed_description>NeuroRx develop NRX-101 , fixed-dose combination oral capsule compose d-cycloserine ( DCS ) lurasidone maintenance remission Acute Suicidal Ideation Behavior ( ASIB ) adult Bipolar Depression follow initial stabilization . The proposed oral combination product intend administered part sequential therapy consist follow 2 component : 1. initial , one-time intravenous ( iv ) infusion ketamine ( 0.5 mg/kg administer 40 min ) , follow one day later 2. twice daily oral capsule NRX 101 ( DCS + lurasidone ) , dose initiated 1 day ketamine administration , titrate 5 day maintenance dose continue 6 week . Each NRX-101 oral capsule contains DCS ( 237.5 175.0 mg ) lurasidone ( 8.25 , 16.5 , 33.0 mg ) . It anticipate subject enter study receive concurrent disorder-directed treatment various predefined combination medication . This treatment regime maintain upon entry study . However , use lurasidone , quetiapine , olanzapine stop study entry , avoid either duplication study drug ( group 1 2 ) undermine control group . The clinical efficacy goal provide extend relief symptom associate ASIB adult Bipolar Disorder , allow effective treatment NRX-101 dosing initiate one day ( 24 hour ) initial stabilization iv ketamine clinic , emergency department , inpatient setting . NRX-101 contains active pharmaceutical ingredient ( APIs ) Food Drug Administration ( FDA ) -approved oral product Seromycin ( Cycloserine Capsules , USP ; ANDA 060593 ; Purdue GMP ) Latuda ( lurasidone HCL ) tablets oral administration ( NDA 200603 ; Sunovion Pharma , Inc. ) . The propose NRX-101 product take advantage unique synergistic confluence 2 approve medication long history safety follow administration single dose ketamine . All component treatment currently FDA-approved use condition ASIB . The goal combine drug single course treatment maximize beneficial effect specific subcomponents overcome potential treatment-limiting side effect associate subcomponents . Beneficial effect propose dosage regimen include 1 ) well-documented pharmacodynamic effect ketamine treat persistent depressive symptom suicidal ideation bipolar disorder ( McCloud , 2015 ; Naughton , 2014 ; Newport , 2015 ; Price , 2014 ) , 2 ) well-documented pharmacodynamic effect oral DCS persistent symptom depression ( Heresco-Levy , 2013 ) 3 ) FDA-approved efficacy lurasidone treatment-resistant depression ( Sunovion Pharmaceuticals , 2013 ) . Due synergistic effect , propose NRX-101 combination capsule also expect avoid minimize significant undesired adverse effect associate usage drug single agent ( eg , negative consequence repeat use ketamine ( JHP Pharmaceuticals , 2012 ) , potential psychotomimetic effect long-term treatment DCS alone ( Kantrowitz , 2010 ) potential akathisia susceptibility increase suicidality associate lurasidone alone ( Sunovion Pharmaceuticals , 2013 ) . The risk ASIB high bipolar depression psychiatric disorder majority currently available antidepressant contraindicate patient bipolar depression . NeuroRx believe propose NRX-101 treatment regimen ( ketamine administration follow NRX-101 ) demonstrate superiority ketamine follow lurasidone ketamine alone delay time document relapse depression bipolar disorder , provide new treatment option ASIB patient . There currently FDA-approved product treatment ASIB . NeuroRx propose NRX-101 fulfill urgent medical need safe effective treatment ASIB . Patients Bipolar Depression ASIB recruit inpatient outpatient setting , follow informed consent , give intravenous infusion ketamine 0.5mg/kg 40 minute . Those exhibit satisfactory clinical response ketamine randomly allocate NRX-101 comparator group . The primary outcome variable time relapse define return baseline either depression suicidality determine treat physician need institute new treatment plan .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Suicide</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Suicidal Ideation</mesh_term>
	<mesh_term>Suicide , Attempted</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : 1 . Male female , 18 65 year age , inclusive , screen . 2 . Able read , understand , provide write , date informed consent prior screen . Participants deem likely comply study protocol communicate study personnel AEs clinically important information . 3 . Diagnosed Bipolar Disorder ( BD ) accord criterion define DSM5 . The diagnosis BD make site psychiatrist support MINI 7.0.2 . The diagnosis confirm remote , independent raters , via teleconference screen visit baseline visit . 4 . Suicidal ideation behavior sufficient severity meet requirement score 4 , 5 CSSRS ( suicide attempt , interrupt attempt , abort attempt , preparatory action toward imminent suicidal behavior , active method , intent +/ plan ) . 5 . A score equal great 20 MADRS item BISS . 6 . In good general health , opinion investigator , ascertain medical history , physical examination ( PE ) ( include measurement seat vital sign ) , clinical laboratory evaluation , electrocardiogram ( ECG ) . 7 . If female , status nonchildbearing potential use acceptable form birth control per follow specific criterion : a. Nonchildbearing potential ( e.g. , physiologically incapable become pregnant , i.e. , permanently sterilize [ status post hysterectomy , bilateral tubal ligation ] , postmenopausal last menses least one year prior screen ) ; Childbearing potential , meet follow criterion : Childbearing potential , include woman use form hormonal birth control , hormone replacement therapy start prior 12 month amenorrhea , use intrauterine device ( IUD ) , monogamous relationship partner vasectomy , sexually abstinent . Negative urinary pregnancy test screening , confirm negative urinary pregnancy test randomization prior receive study treatment . Willing able continuously use one follow method birth control course study , define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly : implant , injectable patch hormonal contraception , oral contraceptive , IUD , doublebarrier contraception , sexual abstinence . The form birth control document screen baseline . 8 . Body mass index 1835 kg/m2 . 9 . Concurrent psychotherapy allow type ( e.g. , supportive , cognitive behavioral , insightoriented ) frequency ( e.g. , weekly monthly ) therapy stable least three month prior screen type frequency therapy expect remain stable course subject 's participation study . 10 . Concurrent hypnotic therapy ( e.g. , zolpidem , zaleplon , melatonin , benzodiazepine trazodone ) allow therapy stable least 4 week prior screen expect remain stable course subject 's participation study . Subjects also continue treatment benzodiazepine use sleep anxiety therapy stable least 4 week prior screen expect remain stable course subject 's participation study . A subject eligible inclusion study follow criterion apply : 1 . Female childbearing potential willing use one specify form birth control study . 2 . Female pregnant breastfeeding . 3 . Female positive pregnancy test screen baseline . 4 . Current diagnosis substance use disorder ( abuse dependence , define DSM5 , exception nicotine dependence ) , screen within 6 month prior screen . 5 . Current Axis I disorder , diagnose screening use MINI 7.0.2 , primary focus treatment BD secondary focus treatment past 6 month . 6 . History schizophrenia schizoaffective disorder , history psychotic symptom . 7 . History anorexia nervosa , bulimia nervosa , eat disorder otherwise specify , within 5 year screen . 8 . Any Axis I Axis II Disorder , screen clinically predominant BD predominant BD time within 6 month prior screen . 9 . Has dementia , delirium , amnestic , cognitive disorder . 10 . Has clinically significant abnormality screen physical examination might affect safety , study participation , confound interpretation study result accord study clinician . 11 . Participation clinical trial investigational drug device within past month concurrent study participation . 12 . Current episode : Hypertension , Stage 1 define systolic blood pressure ≥140 mmHg diastolic blood pressure ≥90 mmHg screen two three measurement least 15 minute apart . Hypertension , Stage 1 define systolic blood pressure ≥155 mmHg diastolic blood pressure ≥99 mmHg Baseline Visit ( Visit 1 ) within 1.5 hour prior ketamine infusion two three measurement least 15 minute apart . Recent myocardial infarction ( within one year ) history myocardial infarction . Syncopal event within past year . Congestive heart failure ( CHF ) New York Heart Association Criteria &gt; Stage 2 Angina pectoris . Heart rate &lt; 50 &gt; 105 beat per minute screen randomization ( Baseline Visit ) . QTcF ( Fridericiacorrected ) ≥450 msec screen randomization ( Baseline Visit ) . 13 . Current history hypertension , antihypertensives purpose lower blood pressure , either increase antihypertensive dose increase number antihypertensive drug use treat hypertension last 2 month . 14 . Chronic lung disease exclude asthma . 15 . Lifetime history surgical procedure involve brain meninges , encephalitis , meningitis , degenerative central nervous system ( CNS ) disorder ( e.g. , Alzheimer 's Parkinson 's Disease ) , epilepsy , mental retardation , disease/procedure/accident/intervention , accord screen clinician , deem associated significant injury malfunction CNS , history significant head trauma within past 2 year . 16 . Presents follow lab abnormality : Subjects diabetes mellitus fulfil follow criterion : Unstable diabetes mellitus define glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % screening . Admitted hospital treatment diabetes mellitus diabetes mellitusrelated illness past 12 week . Not physician care diabetes mellitus . Has dose oral hypoglycemic drug ( ) and/or diet 4 week prior screen . For thiazolidinediones ( glitazones ) period le 8 week . Any clinically significant abnormal laboratory result ( determine investigator medical monitor ) time screen . 17 . Any current past history physical condition investigator 's opinion might put subject risk interfere study result interpretation . 18 . Positive screening urine test drug abuse screening : cocaine , amphetamine , barbiturate , opiate . 19 . Subjects exclusionary laboratory value , require treatment exclusionary concomitant medication define study manual 20 . Subjects exclusionary concomitant psychotropic medication . 21 . Subjects lifetime history illicit PCP/ketamine drug use previous fail use ketamine depression . 22 . Liver Function Tests high 2.5 time upper limit normal define study manual . 23 . Known allergy Lurasidone Latuda , Cycloserine Seromycin , Mannitol , Croscarmellose Sodium , Magnesium Stearate , Silicon Dioxide , and/or HPMC ( hydroxypropylmethylcellulose )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>d-cycloserine</keyword>
	<keyword>lurasidone</keyword>
	<keyword>ketamine</keyword>
	<keyword>randomize control trial</keyword>
</DOC>